Vertex Pharmaceuticals' Kalydeco, or ivacaftor, topped Genetic Engineering & Biotechnology News' list of best-selling drugs that were approved and commercialized last year based on 2012 sales figures. Kalydeco generated sales of $171.6 million. Medivation and Astellas Pharma's Xtandi, or enzalutamide, came in second with $71.5 million, followed by Pfizer's Inlyta, or axitinib, with $70.1 million. Rounding out the top five were Onyx Pharmaceuticals' Kyprolis, or carfilzomib, and Roche Holding's Perjeta, or pertuzumab. The list includes the dates of approval in the U.S. and/or Europe.
20 biggest launches of 2012 were led by Kalydeco and Xtandi
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|